Physician profile
Phyllis C Smith
NPI 1992868343
$2,046.07
in general payments reported to CMS, 2019-2025
14 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $862 · 2024: $727 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $361.89 | 2023-2024 | Arexvy, Bexsero, Fluarix Quadrivalent |
| Myriad Genetic Laboratories, INC. | $264.00 | 2023 | Myrisk |
| Axsome Therapeutics, INC. | $243.64 | 2024-2025 | Symbravo, Auvelity |
| Astrazeneca Pharmaceuticals LP | $187.39 | 2024-2025 | Airsupra, Fasenra |
| Idorsia Pharmaceuticals US INC | $125.88 | 2023 | Quviviq |
| Optinose US, INC. | $125.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $122.09 | 2025 | Cobenfy |
| Genentech USA, INC. | $121.83 | 2024 | Xolair |
| Lilly USA, LLC | $121.83 | 2024 | Zepbound |
| Pharmacosmos Therapeutics INC. | $121.81 | 2023 | Monoferric |
| Janssen Pharmaceuticals, INC | $120.81 | 2023 | Spravato |
| Abbvie INC. | $90.19 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $22.18 | 2025 | Rexulti |
| Medline Industries LP | $17.53 | 2023 | Z-Guard, Medline Industries, INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.